Positron emission tomography in a premenopausal asymptomatic woman: A case report of increased ovarian uptake in a benign condition

International Journal of Gynecological Cancer

Volumn 15, Issue 6, 2005, Pages 1127-1130

  Cottrill, H M ^a   Fitzcharles, E K ^b   Modesitt, Susan C ^a,c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b Lexington Diagnostic Center   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Ovarian cancer; Positron emission tomography; Premenopausal

Indexed keywords

ADULT; ARTICLE; CASE REPORT; CORPUS LUTEUM; DIAGNOSTIC IMAGING; FEMALE; HUMAN; OVARY CYST; POSITRON EMISSION TOMOGRAPHY; PREMENOPAUSE; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; TRANSVAGINAL ECHOGRAPHY;

ADULT; CORPUS LUTEUM; FEMALE; HUMANS; LAPAROSCOPY; OVARIECTOMY; OVARY; POSITRON-EMISSION TOMOGRAPHY; PREMENOPAUSE; SENSITIVITY AND SPECIFICITY;

EID: 30944466470     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2005.00191.x     Document Type: Article

References (14)

1. DiSaia PJ, Creasman WT. Epithelial ovarian cancer. In: DiSaia PJ, Creasman WT, eds. Clinical gynecologic oncology, 5th edn. St. Louis, MO: Mosby Inc., 1997:282-350.
2. 18F]fluoro-2-deoxy-D-glucose in oncology. Part II. The clinical value in detecting and staging primary tumors. J Cancer Res Clin Oncol 2000;126:560-74.
3. Rose PG, Adler LP, Rodriguez M, Faulhaber PF, Abdul-Karim W, Miraldi F. Positron emission tomography for evaluation para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study. J Clin Oncol 1999;17:41-5.
4. Agress H Jr, Cooper BZ. Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET: histopathologic comparison. Radiology 2004;230:417-22.
5. 18F]FDG). Gynecol Oncol 1993;51:197-204.
6. Kubik-Huch RA, Dörffler W, von Schulthess GK et al. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol 2000;10:761-7.
7. Nakamoto Y, Saga T, Ishimori T et al. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer. Am J Radiol 2001;176:1449-54.
8. Jiménez-Bonilla J, Maldonado A, Morales S et al. Clinical impact of 18F-FDG-PET in the suspicion of recurrent ovarian carcinoma based on elevated tumor marker serum levels. Clin Positron Imaging 2000;3:231-6.
9. Karlan BY, Hawkins R, Hoh C et al. Whole-body positron emission tomography with 2(18f)-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma. Gynecol Oncol 1993;51:175-81.
10. Yasuda S, Ide M, Nakahara T, Mochizuki Y, Takaashi W, Shohtsu A. Application of positron emission tomography imaging to cancer screening. Br J Cancer 2000;83:1607-11.
11. Grab D, Flock F, Stöhr I et al. Classification of asymptomatic adnexal masses by ultrasound magnetic resonance imaging and positron emission tomography. Gynecol Oncol 2000;77:454-9.
12. Fenchel S, Grab D, Nuessle K et al. Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings. Radiology 2002;223:780-8.
13. Chander S, Meltzer CC, McCook BM. Physiologic uterine uptake of FDG during menstruation demonstrated with serial combined positron emission tomography and computed tomography. Clin Nucl Med 2002;27:22-4.
14. 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT. J Nucl Med 2004;45:266-71.